November 10, 2025 — Leads & Copy — Revvity, Inc. (NYSE: RVTY) has announced a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions, in a move to enhance its Revvity Signals platform. The acquisition is expected to close late in the fourth quarter of 2025.
ACD/Labs specializes in analytical characterization and molecular design software for the pharmaceutical and material sciences industries. Its tools support analytical and process chemistry within pharmaceutical and chemical research and development workflows, aiding scientists in identifying and characterizing molecules, monitoring purity and quality, and ensuring robust production processes.
The integration of ACD/Labs into Revvity Signals aims to bridge the gap between analytical data and actionable insights, strengthening Revvity’s ability to accelerate scientific innovation. The combined offerings will provide comprehensive support across the scientific workflow, from discovery and development to scale-up and manufacturing.
Kevin Willoe, president of Revvity Signals Software, stated that integrating ACD/Labs’ technologies into the Revvity Signals platform will provide customers with a unified SaaS environment connecting molecular design, analytical science, and manufacturing quality control. Willoe also noted that the acquisition adds meaningful value to Revvity’s portfolio and reinforces the importance of analytical sciences in driving innovation.
Daria Thorp, president and CEO of ACD/Labs, said that joining Revvity Signals brings together two industry leaders with a shared commitment to innovation in scientific software. Thorp anticipates that the merger will expand the reach of ACD/Labs’ technology and deliver unified, end-to-end solutions that empower customers with deeper insight and greater scientific continuity.
ACD/Labs’ industry-leading tools include:
- Spectrus® Platform: Advanced spectral analysis
- Percepta® Platform: AI-driven molecular property and ADMET prediction
- Specialized applications: Katalyst D2D® (parallel and high-throughput experimentation), Luminata® (pharmaceutical chemistry, manufacturing, and controls decision support), and ADMS (enterprise analytical data management)
Revvity reported 2024 revenue of more than $2.7 billion and has approximately 11,000 employees, serving customers in pharmaceutical and biotech, diagnostic labs, academia, and governments across more than 160 countries. Revvity is part of the S&P 500 index.
ACD/Labs has been a provider of scientific software for 30 years, focusing on decision-making and digital transformation in chemical and pharmaceutical R&D. Its science-centric solutions offer harmonized, AI-ready analytical, structural, and molecular information, with FAIR-compliance.
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
This press release contains forward-looking statements regarding future earnings per share, cash flow, revenue growth, and business development opportunities, acquisitions, and divestitures. These statements are based on current assumptions and expectations but are subject to various risk factors that could cause actual results to differ materially.
Risk factors include market declines, economic and political fluctuations, failure to introduce new products, ability to execute and integrate acquisitions, competition, disruptions in supply chains and information technology systems, intellectual property protection, regulatory changes, and economic risks associated with foreign operations, among others.
Revvity disclaims any intention or obligation to update forward-looking statements as a result of developments occurring after the date of this release.
Contact:
Investor Relations
ir@revvity.com
1-888-738-9477
Source: Revvity
